Status:
COMPLETED
Indoleamine 2,3-dioxygenase (IDO) Activity in Patients With Chronic Lymphocytic Leukemia (CLL)
Lead Sponsor:
Tampere University Hospital
Conditions:
CLL
Eligibility:
All Genders
15-85 years
Brief Summary
The Activity of Indoleamine 2,3-dioxygenase in patients with Chronic Lymphocytic Leukemia (CLL) is studied.
Detailed Description
The Activity of Indoleamine 2,3-dioxygenase in patients with Chronic Lymphocytic Leukemia (CLL)is studied in patients and healthly controls.
Eligibility Criteria
Inclusion
- Patients with CLL and lymphocyte count \> 10 x 109/l
Exclusion
- Acute infection
Key Trial Info
Start Date :
February 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2010
Estimated Enrollment :
73 Patients enrolled
Trial Details
Trial ID
NCT01397916
Start Date
February 1 2010
End Date
December 1 2010
Last Update
April 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tampere university Hospital
Tampere, Finland, 33521